Landmark Trial Reports Breakthrough Against Cancers Previously Deemed 'Undruggable'

On May 31, 2026, an audience at the American Society of Clinical Oncology (ASCO) annual meeting rose to its feet after hearing what researchers called the most significant advance against pancreatic cancer in a generation. The drug daraxonrasib, an oral pill taken once daily, nearly doubled median overall survival in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) — from 6.7 months on standard chemotherapy to 13.2 months [1][2]. The results, published simultaneously in the New England Journal of Medicine, represent the first targeted therapy to deliver a statistically significant survival benefit in this disease [3].

Pancreatic cancer kills roughly 50,000 Americans per year and more than 466,000 people worldwide, with a five-year survival rate of approximately 10% [4]. For over 40 years, the protein most responsible for driving these tumors — KRAS — was labeled "undruggable" by the scientific community. That label may now be obsolete, but what it means for patients depends on a series of unanswered questions about access, durability, resistance, and cost.

The Target: Why KRAS Was Called 'Undruggable'

KRAS (Kirsten rat sarcoma viral oncogene homolog) is the most frequently mutated oncogene in human cancer. Mutations in the KRAS gene are present in approximately 90% of pancreatic cancers, roughly 30–40% of colorectal cancers, and about 25% of non-small cell lung cancers (NSCLC) [5][6]. Globally, that translates to millions of patients whose tumors are driven by a protein that, until recently, had no approved direct inhibitor.

The "undruggable" designation stemmed from KRAS's molecular structure. The protein binds GTP (guanosine triphosphate) with extraordinarily high affinity and lacks the surface crevices — hydrophobic pockets — where small-molecule drugs typically latch on [7]. Decades of effort by academic labs and pharmaceutical companies failed to find a way in. RAS, MYC, and TP53 are often grouped together as the "holy trinity" of undruggable cancer targets [8].

The first cracks in this wall appeared in 2013 when Kevan Shokat's lab at UC San Francisco identified a previously unknown pocket on KRAS G12C, a specific mutation found in about 13% of NSCLC and 1–2% of pancreatic cancers [5]. That discovery led to sotorasib (Lumakeras), approved by the FDA in May 2021 as the first-ever direct KRAS inhibitor, followed by adagrasib (Krazati) in 2022. Both target only the G12C mutation in KRAS's inactive ("off") state [6].

The limitation was stark: these drugs addressed a single mutation variant and worked only when KRAS was switched off — a state the protein occupies briefly before cycling back on. For pancreatic cancer patients, whose tumors predominantly carry G12D (35%), G12V (20–30%), or G12R (10–20%) mutations, the first-generation KRAS drugs were largely irrelevant [9].

How Daraxonrasib Works: The Tri-Complex Innovation

Daraxonrasib (formerly RMC-6236) takes a fundamentally different approach. Rather than targeting a single mutation in KRAS's inactive state, it binds to the active, GTP-bound ("on") form of the protein across multiple mutation types — hence Revolution Medicines' term "RAS(ON) multi-selective inhibitor" [10][11].

The structural innovation is a tri-complex mechanism. Daraxonrasib first binds to cyclophilin A, an abundant intracellular chaperone protein, forming a binary complex. This complex then engages the active RAS protein, creating a three-part molecular assembly that blocks RAS from interacting with its downstream effector proteins — shutting off the RAF–MEK–ERK and PI3K–AKT signaling cascades that drive tumor growth [10][11]. The drug can also stimulate GTP hydrolysis in a mutant-selective manner, effectively helping to switch the protein off [11].

This approach has been in development since Revolution Medicines was founded in 2014 in Redwood City, California. The company's RAS(ON) program entered clinical testing in 2022. The FDA granted Breakthrough Therapy designation for daraxonrasib in June 2025 based on early-phase data [1][12].

Source: OpenAlex

Data as of Jan 1, 2026CSV

The surge in KRAS inhibitor research reflects the broader scientific community's investment in cracking this target, with over 112,000 papers published since 2011 and a peak of more than 16,000 in 2023 [13].

The RASolute 302 Trial: Design and Results

The Phase 3 RASolute 302 trial enrolled 500 patients across 59 sites in North America, Europe, and Asia. Patients had metastatic PDAC that had progressed on one prior line of fluoropyrimidine- or gemcitabine-based chemotherapy. They were randomized to receive either oral daraxonrasib (248 patients) or investigator's choice among four chemotherapy regimens (252 patients) [2][14].

Eligibility required an ECOG performance status of 0–1, meaning patients were ambulatory and capable of self-care — a criterion that excludes the sickest patients. Tumor RAS mutational status was documented by local testing, but notably, patients were eligible regardless of specific RAS mutation type, including those with no identified RAS mutation (wild-type), reflecting the drug's broad mechanism [14][15].

At the data cutoff of February 10, 2026, with a median follow-up of 8.5 months [2]:

• Median overall survival (OS): 13.2 months (daraxonrasib) vs. 6.7 months (chemotherapy), a 60% reduction in the risk of death (HR 0.40)
• Progression-free survival: Statistically significant improvement (exact PFS numbers pending full publication detail)
• Objective response rate: Tumor shrinkage was observed in nearly one-third of daraxonrasib patients, compared to about 10% on chemotherapy [16]

The trial met all primary and key secondary endpoints in both the RAS G12 mutant population and the overall intent-to-treat population [2].

Source: NEJM / RASolute 302 Trial

Data as of May 31, 2026CSV

Adverse Events and Safety Profile

Daraxonrasib's side-effect profile differed meaningfully from chemotherapy. The most frequent Grade 3 or higher treatment-related adverse events (events serious enough to require medical intervention) on daraxonrasib were rash (14%) and stomatitis (12%, or mouth sores). By contrast, the most common severe events on chemotherapy were neutropenia (28%, a dangerous drop in infection-fighting white blood cells), anemia (16%), and thrombocytopenia (10%, low platelets) [2][17].

Treatment-related serious adverse events occurred in 10.8% of daraxonrasib patients versus 18.7% on chemotherapy. One death from pneumonitis (lung inflammation) was attributed to daraxonrasib (0.4%); no treatment-related deaths occurred in the chemotherapy arm [2][17].

Perhaps most telling for quality-of-life considerations: only 1.2% of patients on daraxonrasib discontinued treatment due to side effects, compared to 11.2% on chemotherapy [2]. Patients on daraxonrasib also reported significantly slower deterioration in cancer-related pain and overall health status [17].

Source: RASolute 302 Trial Data

Data as of May 31, 2026CSV

Who Funded the Trial — and What Financial Ties Exist

RASolute 302 was sponsored and funded by Revolution Medicines (NASDAQ: RVMD). In June 2025, the company entered a $2 billion funding arrangement with Royalty Pharma, consisting of a synthetic royalty of up to $1.25 billion on daraxonrasib and a senior secured loan of up to $750 million [18]. In April 2026, Revolution Medicines raised an additional $2.225 billion through public offerings of common stock and convertible notes [19].

As a company-sponsored trial, the principal investigators have financial relationships with Revolution Medicines, including consulting fees, advisory board compensation, and equity. These relationships are disclosed in the NEJM publication but warrant scrutiny, as industry-sponsored trials in oncology have historically tended to report more favorable results than independently funded research [3].

The trial's open-label design — both patients and physicians knew which treatment was assigned — is a potential source of bias, particularly for subjective outcomes like quality of life. However, overall survival, the primary endpoint, is the hardest outcome to bias, and the magnitude of the difference (nearly double) is large enough to withstand methodological critiques about blinding [2].

The Cost and Access Question

Revolution Medicines has not disclosed pricing for daraxonrasib, which remains investigational and has not yet received FDA approval. The company has initiated an expanded access program (EAP), authorized by the FDA, to provide the drug to eligible patients with previously treated metastatic PDAC who have no comparable alternative therapy [20][21].

Daraxonrasib was also selected for the FDA Commissioner's National Priority Voucher pilot program, which is intended to accelerate the review of therapies aligned with U.S. national health priorities [2].

However, the history of oncology drug pricing provides cause for concern. Targeted oral cancer therapies routinely cost $10,000 to $20,000 or more per month in the United States. Sotorasib, the first KRAS G12C inhibitor, was priced at approximately $17,900 per month at launch [6]. If daraxonrasib follows similar pricing conventions, a full course of treatment could cost well over $100,000.

The precedent of CAR-T cell therapy is instructive: first approved in 2017 at a price exceeding $373,000 per treatment, CAR-T therapies remain available only at specialized academic medical centers nearly a decade later. PARP inhibitors, first validated in clinical trials in 2009 and approved starting in 2014, took years to penetrate community oncology settings [22]. For a disease like pancreatic cancer, where the median age at diagnosis is 70 and many patients are treated at community hospitals, the gap between trial results and real-world availability can be measured in years and lives.

Resistance: The Known Unknown

Every targeted cancer therapy eventually confronts resistance, and KRAS inhibitors are no exception. Research on sotorasib and adagrasib has documented multiple resistance mechanisms: direct mutations in KRAS that reduce drug binding, amplification of the mutant KRAS gene, and activation of bypass signaling pathways (including MAPK reactivation through receptor tyrosine kinases) [23][24].

Non-mutational resistance has also been observed, including epithelial-to-mesenchymal transition (EMT), YAP pathway activation, and epigenetic reprogramming [23]. Essentially all patients with PDAC treated with first-generation KRAS G12C inhibitors eventually developed progressive disease [24].

Whether daraxonrasib's broader mechanism — targeting multiple RAS variants in the active state — confers greater durability against resistance remains an open question. Early laboratory data suggest that tri-complex inhibitors may face their own resistance pathways [25]. With a median follow-up of only 8.5 months, the trial data cannot yet answer how long responses last or how quickly resistance emerges in the majority of patients.

Who Was — and Wasn't — in the Trial

The RASolute 302 trial enrolled patients across North America, Europe, and Asia, with a median age of 65–66 years [2][14]. Eligibility required adequate organ function and an ECOG performance status of 0–1, which by definition excludes patients who are bedridden or require significant assistance — a considerable fraction of the metastatic pancreatic cancer population.

Detailed racial and ethnic breakdowns from the trial have not been fully published as of this writing. Pancreatic cancer disproportionately affects Black Americans, who have a 25–50% higher incidence rate and worse outcomes compared to white Americans. Whether the trial population reflects this disparity matters for the generalizability of results [4].

Patients were required to have received exactly one prior line of therapy, excluding both treatment-naïve patients and heavily pretreated patients. The trial also enrolled only patients with metastatic disease, not locally advanced unresectable PDAC. These criteria sharpen the statistical signal but narrow the population to whom results directly apply.

The Skeptic's Case: Why Caution Is Warranted

The enthusiasm surrounding these results is real, and it is grounded in data. A 60% reduction in the risk of death is among the largest treatment effects ever observed in a pancreatic cancer trial. But experienced oncologists and biostatisticians have raised several notes of caution:

Short follow-up. At 8.5 months median follow-up, the long-term trajectory is unclear. Many targeted therapies show impressive initial responses that narrow over time as resistance develops. Whether daraxonrasib's survival curves continue to separate or begin to converge will not be known until later data cuts [2].

Comparator arm performance. The median OS of 6.7 months in the chemotherapy arm is consistent with historical data for second-line pancreatic cancer, but the comparator was investigator's choice among four regimens — a design that can introduce variability. Some critics argue that a more standardized or optimized comparator might narrow the gap.

Historical replication rates. A 2019 analysis in the Journal of the National Cancer Institute found that a significant proportion of oncology drugs approved on surrogate endpoints like response rate or progression-free survival did not ultimately demonstrate overall survival benefits. The RASolute 302 trial used OS as its primary endpoint, which is a strength, but 13.2 months median survival, while doubled from standard of care, still means most patients will die of their disease within roughly a year [2].

The "undruggable" framing. Several researchers have noted that RAS was never truly undruggable — it was undrugged. The distinction matters because the "undruggable" label implies a biological impossibility that has been overcome, when in reality it reflected the limits of medicinal chemistry at a given point in time [7][8]. Framing the advance in terms of overcoming an impossible barrier risks setting public expectations higher than the data support.

Open-label bias. While OS is resistant to bias, secondary endpoints such as quality of life and symptom control are more susceptible to placebo effects and reporting differences in open-label trials [2].

The Broader Pipeline and What Comes Next

Daraxonrasib is not the only RAS-targeting drug in development. At least 17 KRAS G12C inhibitors, 5 KRAS G12D inhibitors, and 3 pan-RAS inhibitors are in clinical trials globally [6]. Revolution Medicines itself is testing daraxonrasib in first-line metastatic PDAC (both as monotherapy and in combination with chemotherapy) in additional trials, with updated Phase 1/2 data presented at the 2026 AACR annual meeting [12].

Other approaches to historically undruggable targets are also advancing. APR-246, which aims to reactivate mutant p53, has reached Phase 3 trials in myelodysplastic syndrome [8]. PROTAC degrader molecules, which co-opt the cell's own protein disposal system to destroy target proteins, represent yet another angle of attack [7].

For pancreatic cancer specifically, the combination of daraxonrasib with chemotherapy in the first-line setting may prove more important than the second-line monotherapy data. If the drug can extend survival when administered earlier in the disease course, the clinical impact could be substantially larger.

What This Means for Patients Today

Revolution Medicines has begun shipping daraxonrasib through its expanded access program, which is limited to eligible adult patients at participating institutions with previously treated metastatic PDAC who lack satisfactory alternative therapies [20][21]. The company plans to submit a New Drug Application to the FDA under the National Priority Voucher program, which could accelerate the review timeline [2].

For the roughly 50,000 Americans and 495,000 people worldwide diagnosed with pancreatic cancer each year, the RASolute 302 results offer something that has been rare in this disease: a meaningful extension of life with a better side-effect profile than chemotherapy [4]. Whether that extends to a durable survival benefit, who will be able to access and afford the drug, and how resistance will shape long-term outcomes — these are questions the data cannot yet answer. The forty-year quest to drug the undruggable has reached a milestone. The distance remaining is still unclear.